transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2024-11-4-324-333transmed-953Research ArticleЭНДОКРИНОЛОГИЧЕСКИЕ ЗАБОЛЕВАНИЯMETABOLIC DISEASESК вопросу о новых терапевтических возможностях кисспептинаNovel therapeutic opportunities of kisspeptinhttps://orcid.org/0000-0003-4013-0785НикитинаИ. Л.NikitinaI. L.

Никитина Ирина Леоровна, д.м.н., профессор, заведующий кафедрой детских болезней с клиникой лечебного факультета

Санкт-Петербург

Irina L. Nikitina, doctor of medical sciences, professor, head of the Department of Childhood Diseases with the Clinic of the Faculty of Medicine

Saint Petersburg

nikitina0901@gmail.comКапустинаА. С.KapustinaA. S.

Капустина Анна Сергеевна, врач — детский эндокринолог Университетской клиники

Санкт-Петербург

Anna S. Kapustina, pediatric endocrinologist of the Clinic of the Faculty of Medicine

Saint Petersburg

Kapustina-annna@yandex.ruhttps://orcid.org/0000-0001-6341-7856ЛеоноваИ. А.LeonovaI. A.

Леонова Ирина Александровна, к.м.н., доцент, доцент кафедры детских болезней с клиникой лечебного факультета

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Irina A. Leonova, MD, PhD, аssociate Professor of the Department of Childhood Diseases with the Clinic of the Faculty of Medicine

Akkuratova str., 2, Saint Petersburg, 197341

leonova_ia@mail.ruhttps://orcid.org/0000-0002-0673-8722БайрамовА. А.BairamovA. A.

Байрамов Алекбер Азизович, д.м.н., ведущий научный сотрудник НИЛ детской эндокринологии

Санкт-Петербург

Alekber A. Bairamov, doctor of medical sciences Leading Researcher of the Pediatric Endocrinology Laboratory

Saint Petersburg

alekber@mail.ruФГБУ НМИЦ им. В.А. Алмазова Минздрава РоссииРоссияAlmazov National Medical Research CentreRussian Federation202401092024114324333Copyright © Никитина И.Л., Капустина А.С., Леонова И.А., Байрамов А.А., 20242024Никитина И.Л., Капустина А.С., Леонова И.А., Байрамов А.А.Nikitina I.L., Kapustina A.S., Leonova I.A., Bairamov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/953

Вопросы оптимизации терапевтических возможностей в коррекции расстройств, связанных с нарушениями полового развития, репродуктивной системы, задержки старта пубертата, имеют высокую актуальность, так как в конечном счете данная группа патологий может негативно влиять на демографические показатели, связанные с рождаемостью, фертильностью и в целом с уровнем здоровья молодых людей. В настоящем обзоре представлены современные сведения о роли лиганд-рецепторной системы кисспептина KISS/KISS1R, открытие которой имело революционное значение для расшифровки генеза нейроэндокринной регуляции репродуктивной системы. Также приведен обзор и анализ исследований последних десятилетий о клинико-экспериментальных работах, направленных на изучение кисспептина и его агонистов как потенциальных терапевтических средств лечения ряда расстройств. Приведены данные о позитивном влиянии кисспептина на пульсаторную секрецию ГнРГ и гонадотропинов, что может быть использовано в лечении гипогонадотропного гипогонадизма, нарушений овуляции и других болезней репродуктивной системы. Также освещены данные о возможностях применения кисспептина в коррекции связанной с ожирением неалкогольной жировой болезни печени, остеопенических состояний, психосексуальных расстройств. Разработка аналогов кисспептина потенциально может решить некоторые фармакологические проблемы, возникающие при использовании природных форм кисспептина, хотя для реализации этого потенциала необходимы дальнейшие клинические испытания.

Diseases associated with disorders of sexual development, the reproductive system, delayed of puberty onset are of high relevance. This negatively affect the health of young people, the demographic indicators, fertility and require a search for therapy. This review presents current data on the role of the kisspeptin ligand-receptor system KISS/KISS1R, the discovery of which was of revolutionary significance for deciphering the genesis of neuroendocrine regulation of the reproductive system.

A review and analysis of clinical and experimental research from recent decades, aimed at studying kisspeptin and its agonists as a potential therapeutic approach. Data are presented on the positive effect of kisspeptin on the pulse secretion of GnRH and gonadotropins, which can be used in the treatment of hypogonadotropic hypogonadism, ovulation disorders and other diseases of the reproductive system. Outside the human hypothalamus, kisspeptin and its receptor are expressed in the brain in key limbic and paralimbic regions, and in peripheral tissues. We summarise data on the pharmacological use of kisspeptin in reproductive disorders and fertility treatment, as well as its putative utility in hypoactive sexual desire disorder, osteoporosis and non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated fatty liver disease.

гипогонадизмгонадотропин-рилизинг гормонгонадотропиныкисспептинпубертатрепродуктивная системаgonadotropin-releasing hormonegonadotropinshypogonadismkisspeptinpubertyreproductive systemОбзор выполнен в рамках темы государственного задания № 056-00019-24-00 на 2024 год и на плановый период 2025 и 2026 годов «Оценка эффективности в эксперименте и доклинические исследования нового лекарственного препарата для лечения мужского гипогонадизма» (уникальный номер реестровой записи 720000Ф.99.1.БН62АБ09000).The review was carried out within the framework of the topic of the state assignment № 056-00019-24-00 for 2024 and for the planning period of 2025 and 2026 «Experimental efficacy assessment and preclinical studies of a new drug for the treatment of male hypogonadism» (the unique number of the registry entry 720000Ф.99.1.БН62АБ09000).ReferencesParent A-S, Teilmann G, Juul A, et al. The Timing of Normal Puberty and the Age Limits of Sexual Precocity: Variations around the World, Secular Trends, and Changes after Migration. Endocrin Reviews. 2003;24(5):668–693.Parent A-S, Teilmann G, Juul A, et al. The Timing of Normal Puberty and the Age Limits of Sexual Precocity: Variations around the World, Secular Trends, and Changes after Migration. Endocrin Reviews. 2003;24(5):668–693.Дедов И.И., Петеркова В.А. Детская эндокринология. М.: Универсум Паблишинг, 2006. 600 с.Dedov II, Peterkova VA. Pediatric endocrinology. M.: Universum Publishing, 2006. P. 600. In RussianНикитина И.Л. Детская эндокринология. Ростов-на Дону: Феникс, 2006. 224 с.Nikitina IL. Pediatric endocrinology. Rostov-onDon: Phoenix, 2006. P. 224. In RussianAbreu AP, Kaiser UB. Pubertal development and regulation. Lancet Diabetes Endocrinol. 2016; 4(3): 254– 264. DOI: 10.1016/S2213-8587(15)00418-0.Abreu AP, Kaiser UB. Pubertal development and regulation. Lancet Diabetes Endocrinol. 2016; 4(3): 254– 264. DOI: 10.1016/S2213-8587(15)00418-0.Ojeda SR, Lomniczi A, Sandau U, et al. New concepts on the control of the onset of puberty. In Loche S, Cappa M, Ghizzoni L, et al. Pediatric Neuroendocrinology: Endocr Dev. Basel, Karger. 2010. Vol. 17. P. 44–51.Ojeda SR, Lomniczi A, Sandau U, et al. New concepts on the control of the onset of puberty. In Loche S, Cappa M, Ghizzoni L, et al. Pediatric Neuroendocrinology: Endocr Dev. Basel, Karger. 2010. Vol. 17. P. 44–51.Lomniczi A, Ojeda SR. The emerging role of epigenetics in the regulation of female puberty: in Bourguignon J-P, Parent A-S (eds): Puberty from bench to clinic. Lessons for clinical management of pubertal disorders. Endocr Dev. Basel, Karger. 2016. Vol. 29. P. 1–16.Lomniczi A, Ojeda SR. The emerging role of epigenetics in the regulation of female puberty: in Bourguignon J-P, Parent A-S (eds): Puberty from bench to clinic. Lessons for clinical management of pubertal disorders. Endocr Dev. Basel, Karger. 2016. Vol. 29. P. 1–16.Willemsen RH, Dunger DB. Normal variations in pubertal timing: genetic determinants in relation to growth and adiposity: in Bourguignon J-P, Parent A-S (eds): Puberty from bench to clinic. Lessons for clinical management of pubertal disorders. Endocr Dev. Basel, Karger. 2016. Vol. 29. P. 17–35.Willemsen RH, Dunger DB. Normal variations in pubertal timing: genetic determinants in relation to growth and adiposity: in Bourguignon J-P, Parent A-S (eds): Puberty from bench to clinic. Lessons for clinical management of pubertal disorders. Endocr Dev. Basel, Karger. 2016. Vol. 29. P. 17–35.Bourguignon J-P, Parent A-S, Mullis PE. Puberty from Bench to Clinic. 1st edition. Karger. 2016. 263 p.Bourguignon J-P, Parent A-S, Mullis PE. Puberty from Bench to Clinic. 1st edition. Karger. 2016. 263 p.De Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003; 100(19):10972–6. DOI: 10.1073/pnas.1834399100.De Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003; 100(19):10972–6. DOI: 10.1073/pnas.1834399100.Tsoutsouki J, Abbara A, Dhillo W. Novel therapeutic avenues for kisspeptin. Current Opinion in Pharmacology. 2022; 67:102319. doi.org/10.1016/j.coph.2022.102319.Tsoutsouki J, Abbara A, Dhillo W. Novel therapeutic avenues for kisspeptin. Current Opinion in Pharmacology. 2022; 67:102319. doi.org/10.1016/j.coph.2022.102319.Mills EG, Yang L, Abbara A, et al. Current perspectives on kisspeptins role in behaviour. Front Endocrinol (Lausanne). 2022; 13: 928143.Mills EG, Yang L, Abbara A, et al. Current perspectives on kisspeptins role in behaviour. Front Endocrinol (Lausanne). 2022; 13: 928143.Comninos AN, Hansen MS, Courtney A, et al. Acute effects of kisspeptin administration on bone metabolism in healthy men. J Clin Endocrinol Metab. 2022, 107:1529–1540, https://doi.org/10.1210/clinem/dgac117.Comninos AN, Hansen MS, Courtney A, et al. Acute effects of kisspeptin administration on bone metabolism in healthy men. J Clin Endocrinol Metab. 2022, 107:1529–1540, https://doi.org/10.1210/clinem/dgac117.Guzman S, Dragan M, Kwon H, et al. Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. J Clin Invest. 2022 May 16;132(10):e145889.Guzman S, Dragan M, Kwon H, et al. Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. J Clin Invest. 2022 May 16;132(10):e145889.Tsoutsouki J, Patel B, Comninos AN, et al. Kisspeptin in the prediction of pregnancy complications. Front Endocrinol. (Lausanne). 2022; 13: 942664. doi.org/10.3389/fendo.2022.942664.Tsoutsouki J, Patel B, Comninos AN, et al. Kisspeptin in the prediction of pregnancy complications. Front Endocrinol. (Lausanne). 2022; 13: 942664. doi.org/10.3389/fendo.2022.942664.Scott G, Ahmad I, Howard K, et al. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men. Br J Clin Pharmacol. 2013; 75(2): 381–91 DOI: 10.1111/j.1365-2125.2012.04385.x.Scott G, Ahmad I, Howard K, et al. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men. Br J Clin Pharmacol. 2013; 75(2): 381–91 DOI: 10.1111/j.1365-2125.2012.04385.x.Abbara A, Eng PC, Phylactou M, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020; 130:6739–6753. DOI: 10.1172/JCI139681.Abbara A, Eng PC, Phylactou M, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020; 130:6739–6753. DOI: 10.1172/JCI139681.Abbara A, Clarke SA, Dhillo WS. Clinical potential of kisspeptin in reproductive health. Trends Mol Med. 2021; 27:807–823.Abbara A, Clarke SA, Dhillo WS. Clinical potential of kisspeptin in reproductive health. Trends Mol Med. 2021; 27:807–823.Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005; Dec, 90:6609–6615.Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005; Dec, 90:6609–6615.Chan Y-M, Butler JP, Pinnell NE, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011 Jun;96(6):E908–15.Chan Y-M, Butler JP, Pinnell NE, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011 Jun;96(6):E908–15.George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011 Aug;96(8):E1228–36. DOI: 10.1210/jc.2011-0089.George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011 Aug;96(8):E1228–36. DOI: 10.1210/jc.2011-0089.Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007; 92:3958–3966.Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007; 92:3958–3966.Mills EG, Swedrowska M, Thurston L, et al. Intranasal kisspeptin administration stimulates reproductive hormone secretion in healthy men [cited 2022 Aug 12] Endocr Abstr. 2021 Oct 18:77.Mills EG, Swedrowska M, Thurston L, et al. Intranasal kisspeptin administration stimulates reproductive hormone secretion in healthy men [cited 2022 Aug 12] Endocr Abstr. 2021 Oct 18:77.Jayasena CN, Nijher GMK, Abbara A, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010; 88:840–847.Jayasena CN, Nijher GMK, Abbara A, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010; 88:840–847.Jayasena CN, Nijher GMK, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009; 94: 4315–4323.Jayasena CN, Nijher GMK, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009; 94: 4315–4323.Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. Available from: https://academic.oup.com/jcem/article/96/12/E1963/2834843.Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. Available from: https://academic.oup.com/jcem/article/96/12/E1963/2834843.Jayasena CN, Comninos AN, Veldhuis JD, et al. A single injection of kisspeptin-54 temporarily increases luteinizing hormone pulsatility in healthy women [cited 2022 Jun 20] Clin Endocrinol. 2013; 79:558–563.Jayasena CN, Comninos AN, Veldhuis JD, et al. A single injection of kisspeptin-54 temporarily increases luteinizing hormone pulsatility in healthy women [cited 2022 Jun 20] Clin Endocrinol. 2013; 79:558–563.Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011; 96:E1963–E72.Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011; 96:E1963–E72.Chan Y-M, Butler JP, Sidhoum VF, et al. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. E1458 jcem.endojournals.org J Clin Endocrinol Metab. 2012; 97.Chan Y-M, Butler JP, Sidhoum VF, et al. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. E1458 jcem.endojournals.org J Clin Endocrinol Metab. 2012; 97.George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol. 2013; 79:100–104.George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol. 2013; 79:100–104.Abbara A, Narayanaswamy S, Izzi-Engbeaya C, et al. Hypothalamic response to kisspeptin-54 and pituitary response to gonadotropinreleasing hormone are preserved in healthy older men. Neuroendocrinology. 2018; 106:401–410.Abbara A, Narayanaswamy S, Izzi-Engbeaya C, et al. Hypothalamic response to kisspeptin-54 and pituitary response to gonadotropinreleasing hormone are preserved in healthy older men. Neuroendocrinology. 2018; 106:401–410.Matsui H, Masaki T, Akinaga Y, et al. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide. Eur J Pharmacol. 2014; 735:77–85.Matsui H, Masaki T, Akinaga Y, et al. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide. Eur J Pharmacol. 2014; 735:77–85.Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:1413–1439.Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:1413–1439.Abbara A, Islam R, Clarke SA, et al. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment. Clin Endocrinol. 2018;88:920–927.Abbara A, Islam R, Clarke SA, et al. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment. Clin Endocrinol. 2018;88:920–927.Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014; 124:3667–3677.Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014; 124:3667–3677.Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger Oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100: 3322–3331.Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger Oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100: 3322–3331.Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomizedcontrolled trial. Hum Reprod. 2017;32:1915–1924.Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomizedcontrolled trial. Hum Reprod. 2017;32:1915–1924.Abbara A, Hunjan T, Ho VNA, et al. Endocrine requirements for oocyte maturation following hCG, GnRH agonist, and kisspeptin during IVF. In Treatment. Lausanne: Front Endocrinol. 2020 Oct 6:11.Abbara A, Hunjan T, Ho VNA, et al. Endocrine requirements for oocyte maturation following hCG, GnRH agonist, and kisspeptin during IVF. In Treatment. Lausanne: Front Endocrinol. 2020 Oct 6:11.Abbara A, Clarke SA, Dhillo WS. Novel concepts for inducing final oocyte maturation in in vitro fertilization treatment. Endocr Rev 2018 Oct, 39:593–628.Abbara A, Clarke SA, Dhillo WS. Novel concepts for inducing final oocyte maturation in in vitro fertilization treatment. Endocr Rev 2018 Oct, 39:593–628.Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014; 99:E953–E961.Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. J Clin Endocrinol Metab. 2014; 99:E953–E961.Castellano JM, Navarro VM, FernándezFernández R, et al. Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology. 2005;146:3917–3925.Castellano JM, Navarro VM, FernándezFernández R, et al. Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology. 2005;146:3917–3925.Chan Y-M, Lippincott MF, Kusa TO, et al. Divergent responses to kisspeptin in children with delayed puberty. JCI Insight. 2018;19;3(8):e99109. DOI: 10.1172/jci.insight.99109.Chan Y-M, Lippincott MF, Kusa TO, et al. Divergent responses to kisspeptin in children with delayed puberty. JCI Insight. 2018;19;3(8):e99109. DOI: 10.1172/jci.insight.99109.Chan Y-M, Lippincott MF, Barroso PS, et al. Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay. J Clin Endocrinol Metab. 2020;105(8):e2717–e2725. DOI: 10.1210/clinem/dgaa162.Chan Y-M, Lippincott MF, Barroso PS, et al. Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay. J Clin Endocrinol Metab. 2020;105(8):e2717–e2725. DOI: 10.1210/clinem/dgaa162.Никитина И.Л. Ожирение у детей и подростков: проблема, пути решения. Обзор российских и международных рекомендаций. Лечащий врач. 2018;1: 31–36.Nikitina IL. Obesity in children and adolescents: problem, solutions. Review of Russian and international recommendations. Attending doctor. 2018;1: 31–36 In RussianMills EG, Yang L, Abbara A, et al. Current perspectives on kisspeptins role in behaviour. Front Endocrinol (Lausanne). 2022;13. https://doi.org/10.3389/fendo.2022.928143.Mills EG, Yang L, Abbara A, et al. Current perspectives on kisspeptins role in behaviour. Front Endocrinol (Lausanne). 2022;13. https://doi.org/10.3389/fendo.2022.928143.Yang L, Demetriou L, Wall MB, et al. Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men. JCI Insight. 2020; 5. https://doi.org/10.1172/jci.insight.133633.Yang L, Demetriou L, Wall MB, et al. Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men. JCI Insight. 2020; 5. https://doi.org/10.1172/jci.insight.133633.Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017 Feb 1, 127:709–719, https://doi.org/10.1172/JCI89519.Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017 Feb 1, 127:709–719, https://doi.org/10.1172/JCI89519.Wang F-S, Chen H, Wu Z-Y, et al. KISS1 expression in osteosarcoma: high in Chinese clinical cases, but lower in cell lines. Asian Pac J Cancer Prev APJCP. 2011; 12:3229–3234.Wang F-S, Chen H, Wu Z-Y, et al. KISS1 expression in osteosarcoma: high in Chinese clinical cases, but lower in cell lines. Asian Pac J Cancer Prev APJCP. 2011; 12:3229–3234.Dotterweich J, Tower RJ, Brandl A, et al. The KISS1 receptor as an in vivo microenvironment imaging biomarker of multiple myeloma bone disease. PLoS One. 2016 May 9;11(5):e0155087.Dotterweich J, Tower RJ, Brandl A, et al. The KISS1 receptor as an in vivo microenvironment imaging biomarker of multiple myeloma bone disease. PLoS One. 2016 May 9;11(5):e0155087.de Sousa IO, Diniz ET, Marques TF, et al. Shortterm bone marker responses to teriparatideand strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metabol. 2010; 54:244–249.de Sousa IO, Diniz ET, Marques TF, et al. Shortterm bone marker responses to teriparatideand strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metabol. 2010; 54:244–249.

The authors declare that there are no conflicts of interest present.